NCT01203254

Colesevelam for the Treatment of Bile Acid Malabsorption in Patients With Crohn's Disease

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 34 (actual)
• Sponsor: Florian Beigel · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the efficacy of cholestagel to reduce the frequency of soft and liquid stools per day in patients with CD in clinical remission with symptoms of BAM and to assess the improvement in stool consistency and quality of life in these patients and to assess the safety of cholestagel.

Conditions

• Crohns Disease
• Bile Acid Malabsorption

Interventions

Type	Name	Description
DRUG	Colesevelam	Colesevelam 625 mg tablet; 3 times daily 2 tablets
DRUG	Placebo	Placebo tablet: 3 times daily 2 tablets

Timeline

• Start date: 2010-10-01
• Primary completion: 2013-03-01
• Completion: 2013-03-01
• First posted: 2010-09-16
• Last updated: 2013-04-18

Locations

6 sites across 1 country: Germany